Trial intelligence / Profile preview

Effectiveness of Seasonal Malaria Chemoprevention in Koulikoro, Mali

NCT04149106Phase 3

Key facts

Status: Unknown
Start: Jul 2019
Primary completion: Dec 2022
Countries: 1
Sponsor: University Clinical Research Center
Modality: Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands

Drugs: dihydroartemisinin + piperaquine
Conditions: Malaria

Overview

Phase 3, randomised, open-label trial of dihydroartemisinin + piperaquine in Malaria (3 arms), sponsored by University Clinical Research Center. Primary endpoint: Malaria incidence among cohort in 2 years period. Status: unknown.

Design

3 arms

Study design: RandomizedOpen-label

Standard
SMC with SP+AQ for children < 5 years.
Extension
SMC with SP+AQ for children < 10 years.
Alternative
SMC with DHA-PQ for children < 10 years.

Who it enrols

Children aged 3 months to 119 months residing in the village, without chronic diseases or allergies to study drugs.

Endpoints

Primary

Malaria incidence among cohort in 2 years period2 years

Secondary

Malaria infection prevalence at the start and the end of malaria transmission season2 years
Drug resistance marker prevalence in two 2 years period1 year
SMC coverage and treatment compliance during malaria transmission season2 years

Beyond the preview

Go deeper on NCT04149106.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04149106.